NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity PAR-19-194 from the NIH Guide for Grants and Contracts. The overall purpose of this funding opportunity announcement (FOA) is to stimulate the development of novel microbial-based cancer therapies, especially for conditions where conventional cancer therapies are inadequate, such as poorly vascularized, hypoxic, solid tumors, dormant or slowly dividing cells resistant to current interventions, and brain tumors. Utilizing bacteria, archaebacteria, bacteriophages and other non-virus microorganisms, this initiative will support research projects designed to study the underlying mechanisms of the complex interactions between microorganisms, tumor, and immune system. The FOA also aims to support research into the use of microorganisms as delivery vehicles for cancer treatment and to complement or synergize with current therapies. This FOA will accept basic mechanistic and preclinical studies in cell culture and animal models in accordance with the state of the science. Applicants responding to this FOA must address both the microbial and the tumor aspects of microbial-based cancer therapy. Complex microbial-tumor interactions are best addressed with a multidisciplinary approach. The purpose of this FOA is to encourage basic or applied, multidisciplinary research collaborations between investigators from areas relevant to microbial-based cancer therapy, such as microbiology, oncology, immunology, and cellular and molecular cancer biology. The proposed projects should be state of the art and aim to advance pre-clinical development of novel microbial-based anticancer therapeutic agents, or study the complex biology involved in the interplay of microbe-tumor-immune system. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research, and should apply an integrative approach to increase our understanding of biological, or translational aspects of microbial-based anticancer therapeutic agents.
Funding Opportunity PAR-19-193 from the NIH Guide for Grants and Contracts. The overall purpose of this funding opportunity announcement (FOA) is to stimulate the development of novel microbial-based cancer therapies, especially for conditions where conventional cancer therapies are inadequate, such as poorly vascularized, hypoxic, solid tumors, dormant or slowly dividing cells resistant to current interventions, and brain tumors. Utilizing bacteria, archaebacteria, bacteriophages and other non-virus microorganisms, this initiative will support research projects designed to study the underlying mechanisms of the complex interactions between microorganisms, tumor, and immune system. The FOA also aims to support research into the use of microorganisms as delivery vehicles for cancer treatment and to complement or synergize with current therapies. This FOA will accept basic mechanistic and preclinical studies in cell culture and animal models in accordance with the state of the science. Applicants responding to this FOA must address both the microbial and the tumor aspects of microbial-based cancer therapy. Complex microbial-tumor interactions are best addressed with a multidisciplinary approach. The purpose of this FOA is to encourage basic or applied, multidisciplinary research collaborations between investigators from areas relevant to microbial-based cancer therapy, such as microbiology, oncology, immunology, and cellular and molecular cancer biology. The proposed projects should be state of the art and aim to advance pre-clinical development of novel microbial-based anticancer therapeutic agents, or study the complex biology involved in the interplay of microbe-tumor-immune system. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research, and should apply an integrative approach to increase our understanding of biological, or translational aspects of microbial-based anticancer therapeutic agents.
Funding Opportunity PAR-19-190 from the NIH Guide for Grants and Contracts. The purpose of this program is to advance comprehensive quality surveillance and provide the state of quality for all regulated sites and products. Using predictive analytics, data mining, and other quantitative tools, this research program will expand the knowledge base related to site and product quality, especially for high-risk foreign facilities and their products
Notice NOT-DA-19-024 from the NIH Guide for Grants and Contracts
Funding Opportunity PA-19-188 from the NIH Guide for Grants and Contracts. The purpose of the Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent F32) is to support research training of highly promising postdoctoral candidates who have the potential to become productive, independent investigators in scientific health-related research fields relevant to the missions of the participating NIH Institutes and Centers. Applications are expected to incorporate exceptional mentorship. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.
Funding Opportunity PA-19-196 from the NIH Guide for Grants and Contracts. The purpose of this Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research award is to enhance the diversity of the health-related research workforce by supporting the research training of predoctoral students from diverse backgrounds, including those from population groups that have been shown to be underrepresented in the biomedical, behavioral, or clinical research workforce, such as underrepresented racial and ethnic groups and those with disabilities
Funding Opportunity PAR-19-189 from the NIH Guide for Grants and Contracts. The purpose of this funding announcement is to encourage pilot research that is not an immediate precursor to testing a service intervention but is consistent with NIMH priorities for services research. While NIMH now requires use of an experimental therapeutics model for all intervention studies, there is recognition that some mission-relevant areas of services research do not involve clinical trials.
Funding Opportunity RFA-OD-19-019 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite R01 applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). The awards under this FOA will be administered by NIH using funds that have been made available through FDA CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health.
Notice NOT-OD-19-078 from the NIH Guide for Grants and Contracts
Notice NOT-TR-19-016 from the NIH Guide for Grants and Contracts
Notice NOT-GM-19-022 from the NIH Guide for Grants and Contracts
Ruth L. Kirschstein National Research Service Award (NRSA) Individual Senior Fellowship (Parent F33)
Funding Opportunity PA-19-187 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) awards senior individual research training fellowships to experienced scientists who wish to make major changes in the direction of their research careers or who wish to broaden their scientific background by acquiring new research capabilities as independent investigators in research fields relevant to the missions of participating NIH Institutes and Centers. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.
Notice NOT-AR-19-036 from the NIH Guide for Grants and Contracts
Notice NOT-AT-19-022 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-CA-19-044 from the NIH Guide for Grants and Contracts. This FOA will invite U01 applications in the specific area of cancer immunotherapy-related adverse events. Investigators are encouraged to submit applications that focus on mechanisms of immune reactivity/tolerance and/or autoimmune pathways that could be applied to improving immunotherapeutic approaches while simultaneously eliminating or reducing the severity of inflammatory or autoimmune responses. A related area of interest is studies designed to enhance the target specificity of immunotherapeutic reagents, to reduce or prevent irAEs. An additional synergistic focus of interest is the identification of predictive biomarkers of cancer patients at risk for developing irAEs. Understanding risk factors for developing an irAE would better inform patient stratification at the start of therapy and influence clinical monitoring. Achieving the goals of the RFA should establish a deeper understanding of the origins and activation pathways leading to inflammatory or autoimmune adverse events that currently limit the use of various immunotherapy regimens in patients.
Funding Opportunity RFA-FD-19-004 from the NIH Guide for Grants and Contracts. The objective of this FOA is the development, implementation, and management of a funding system in which State, Tribal, and Territorial Grade A Milk Safety and National Shellfish Sanitation regulatory programs can apply and be subawarded funds to support technical training and equipment purchases, and to improve the implementation of the Grade "A" Milk Safety Program and the National Shellfish Sanitation Program (NSSP). Funds may be awarded to up to two non-profit association/organization(s), upon which they will subsequently administer and subaward funds to State, Tribal, and Territorial regulatory agencies for facilitating improvements to and advancing the Grade A Milk Safety Program and the National Shellfish Sanitation Program.
Notice NOT-CA-19-026 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-FD-19-006 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for UG3/UH3 cooperative agreements to support the development of a publicly available core set(s) of COAs and their related endpoints for specific disease indications. The UG3/UH3 Phase Innovation Award Cooperative Agreement involves 2 phases. The UG3 phase will provide funding for 1 to 2 years to conduct planning activities. The UH3 phase will provide funding for 3 to 4 years to projects that successfully complete the planning activities and reach the projected milestones set in the UG3 phase. UH3 phase awards will be awarded after administrative review of eligible UG3 phase awards that have met the scientific milestone and feasibility requirements necessary for UH3 phase implementation. The number of awards is dependent on the availability of funds. The UG3/UH3 application must be submitted as a single application, and applicants should note specific instructions for each phase in this FOA. The total award project period will not exceed 5 years.
Notice NOT-EB-19-003 from the NIH Guide for Grants and Contracts
Notice NOT-HL-19-682 from the NIH Guide for Grants and Contracts